PortfoliosLab logoPortfoliosLab logo
ISIN
US2288951088
CUSIP
228895108
IPO Date
Jan 21, 1997

Highlights

Market Cap
$27.57M
Enterprise Value
$28.17M
EPS (TTM)
-$0.31
Total Revenue (TTM)
$23.35M
Gross Profit (TTM)
$18.16M
EBITDA (TTM)
-$1.03M
Year Range
$2.72 - $5.43
Target Price
$8.50
ROA (TTM)
-4.06%
ROE (TTM)
13.89%
Avg. Volume (1M)
12K
Avg. Volume Value (1M)
$41.83K

Share Price Chart


Loading charts...

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Cryo-Cell International, Inc.

Often compared with CCEL:
CCEL vs. MUSACCEL vs. LLY

Performance

CCEL Performance Chart

Cryo-Cell International, Inc. (CCEL) is down 0.6% since the beginning of the year. At $3 per share, CCEL is trading 37.0% below its 52-week high of $5. Investors who bought $1,000 worth of CCEL shares 5 years ago would now be looking at an investment worth $464.


Loading charts...

Benchmark

Compare this symbol against anything

Returns By Period

Cryo-Cell International, Inc. (CCEL) has returned -0.58% so far this year and -31.05% over the past 12 months. Over the last ten years, CCEL has returned 0.84% per year, falling short of the S&P 500 Index benchmark, which averaged 13.26% annually.


Cryo-Cell International, Inc.

1D
1.79%
1M
2.40%
6M
3.01%
YTD
-0.58%
1Y
-31.05%
3Y*
-12.62%
5Y*
-14.24%
10Y*
0.84%
ALL TIME*
5.03%

Benchmark (S&P 500 Index)

1D
0.70%
1M
0.09%
6M
7.94%
YTD
9.41%
1Y
20.07%
3Y*
17.84%
5Y*
11.25%
10Y*
13.26%
ALL TIME*
8.09%
*Multi-year figures are annualized to reflect compound growth (CAGR)

CCEL Monthly Returns History

Based on dividend-adjusted daily data since Feb 23, 2011, CCEL's average daily return is +0.08%, while the average monthly return is +1.12%. At this rate, an investment would double in approximately 5.2 years.

Historically, 44% of months were positive and 56% were negative. The best month was Apr 2023 with a return of +107.0%, while the worst month was Feb 2018 at -25.7%. The longest winning streak lasted 10 consecutive months, and the longest losing streak was 9 months.

On a daily basis, CCEL closed higher 34% of trading days. The best single day was Jul 1, 2015 with a return of +32.2%, while the worst single day was Jun 26, 2026 at -24.5%.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2026-3.49%2.41%4.41%-3.66%-1.46%-5.34%7.21%-0.58%
20255.13%4.73%-19.37%-17.58%0.40%1.37%-8.48%-1.05%-1.28%-2.80%-4.66%-20.00%-50.65%
2024-9.39%-0.19%43.46%11.39%-1.08%-7.42%-1.97%-16.89%2.74%15.23%21.60%-14.53%32.67%
2023-4.49%-5.45%-20.94%106.95%-22.40%25.37%-6.42%5.36%-12.26%-0.19%1.90%7.48%35.93%
2022-22.16%-9.97%-6.15%-17.96%-2.08%-3.75%-1.36%26.63%-5.72%-18.20%-12.42%-3.20%-58.46%
20215.19%11.11%1.11%-4.40%-0.57%3.70%2.45%26.22%4.40%3.63%-1.35%-6.30%50.65%

Benchmark Metrics

Cryo-Cell International, Inc. has an annualized alpha of 19.76%, beta of 0.14, and R2 of 0.00 versus S&P 500 Index. Calculated based on daily prices since February 23, 2011.

  • This stock participated in 39.84% of S&P 500 Index downside but only 34.57% of its upside - more exposed to losses than it benefited from rallies.
  • Beta of 0.14 may look defensive, but with R2 of 0.00 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
  • R2 of 0.00 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

Alpha
19.76%
Beta
0.14
0.00
Upside Capture
34.57%
Downside Capture
39.84%

Return for Risk

Risk / Return Rank

CCEL ranks 24 for risk / return — above 24% of stocks peers on PortfoliosLab. Its historical combined result is below the peer median.


CCEL Risk / Return Rank: 2424
Overall Rank
CCEL Sharpe Ratio Rank: 2424
Sharpe Ratio Rank
CCEL Sortino Ratio Rank: 2626
Sortino Ratio Rank
CCEL Omega Ratio Rank: 2626
Omega Ratio Rank
CCEL Calmar Ratio Rank: 2121
Calmar Ratio Rank
CCEL Martin Ratio Rank: 2424
Martin Ratio Rank
The rank (0–100) uses a weighted average of the Sharpe, Sortino, Omega, Calmar, and Martin percentile ranks for the trailing 12 months. Higher means stronger historical risk-adjusted performance within the peer group.

Risk / Return Metrics

The table below present risk-adjusted performance metrics for Cryo-Cell International, Inc. (CCEL) and compare them to S&P 500 Index.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


CCELBenchmarkDifference
Sharpe ratioReturn per unit of total volatility

-1.86

Sortino ratioReturn per unit of downside risk

-2.24

Omega ratioGain probability vs. loss probability

0.96

1.25

-0.29

Calmar ratioReturn relative to maximum drawdown

-0.62

2.00

-2.62

Martin ratioReturn relative to average drawdown

-0.95

8.49

-9.44

Dividends

Dividend History

Cryo-Cell International, Inc. provided a 0.00% dividend yield over the last twelve months, with an annual payout of $0.00 per share.


0.00%5.00%10.00%15.00%20.00%$0.00$0.20$0.40$0.60$0.802022202320242025
Dividends
Dividend Yield
PeriodTTM2025202420232022
Dividend$0.00$0.40$0.25$0.00$0.90

Dividend yield

0.00%11.63%3.37%0.00%21.28%

Monthly Dividends

The table displays the monthly dividend distributions for Cryo-Cell International, Inc.. The dividends shown in the table have been adjusted to account for any splits that may have occurred.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2026$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00
2025$0.00$0.25$0.00$0.00$0.15$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.40
2024$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.25$0.00$0.25
2023$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00
2022$0.90$0.00$0.00$0.00$0.90

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading charts...

Worst Drawdowns

The table below displays the maximum drawdowns of the Cryo-Cell International, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Cryo-Cell International, Inc. was 76.11%, occurring on Mar 28, 2023. The portfolio has not yet recovered.

The current Cryo-Cell International, Inc. drawdown is 69.89%.


Drawdown

Fall

Recovery

Underwater

Related event

-76.11%Mar 2023
1y 6mo
4y 11moSep 2021 - now
-44.72%Mar 2020
2y 1mo11mo 21d
3y 1moJan 2018 - Mar 2021
COVID crash2020
-35.95%Jun 2015
8mo 6d2mo 18d
10mo 24dOct 2014 - Aug 2015
-29.96%Dec 2013
1y 17d4mo 27d
1y 5moNov 2012 - May 2014
-28.00%Aug 2012
18d2mo 28d
3mo 16dJul 2012 - Nov 2012

Drawdown Indicators


CCELBenchmarkDifference

Max Drawdown

Largest peak-to-trough decline

-76.11%

-56.78%

-19.33%

Max Drawdown (1Y)

Largest decline over 1 year

-45.57%

-9.10%

-36.47%

Max Drawdown (3Y)

Largest decline over 3 years

-66.28%

-18.90%

-47.38%

Max Drawdown (5Y)

Largest decline over 5 years

-76.11%

-25.43%

-50.68%

Max Drawdown (10Y)

Largest decline over 10 years

-76.11%

-33.92%

-42.19%

Current Drawdown

Current decline from peak

-69.89%

-1.58%

-68.31%

Average Drawdown

Average peak-to-trough decline

-25.41%

-10.70%

-14.71%

Ulcer Index

Depth and duration of drawdowns from previous peaks

29.63%

2.14%

+27.49%

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading charts...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Cryo-Cell International, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Valuation

The Valuation section provides an overview of how Cryo-Cell International, Inc. is priced in the market compared to other companies in the Medical Care Facilities industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PS Ratio

This chart shows the Price-to-Sales (P/S) ratio for CCEL relative to other companies in the Medical Care Facilities industry. Currently, CCEL has a P/S ratio of 1.2. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items
Portfolio Analyzer

Build a portfolio with CCEL

Add Cryo-Cell International, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Analyzer with CCEL